Dignify Therapeutics has entered a licensing deal with Aayam Therapeutics of San Jose, California, to develop a compound and related molecules focused on bladder and bowel disorders.

RESEARCH TRIANGLE PARK, N.C, Oct. 22, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating ...

Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, announced that Tony DiTonno, CEO and Executive Chairman, will provide a status update on the ...

Dignify Therapeutics, a virtual drug development company in Research Triangle Park, continues to secure federal government grants. Here's a look at the company.

Dignify's lead drug program, DTI-301, is a suppository that patients use as needed for bowel evacuation. DTI-301 induces defecation within 5-10 minutes, with minimal absorption and systemic exposure.

RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical device development company focused on restoring bowel and bladder control ...

Dignify Therapeutics has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant in the amount of $159,000 from the Eunice Kennedy Shriver National Institute of Child Health and ...